Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PIDD CRISPR/Cas9 KO Plasmid (h): sc-403439
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PIDD CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PIDD genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PIDD Antibody (B-5): sc-514981
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PIDD CRISPR/Cas9 KO Plasmid (h) | sc-403439 | 20 µg | $397.00 |
Overview
PIDD1 encodes the p53-induced death domain protein PIDD, a signaling scaffold implicated in cellular stress responses and apoptotic regulation. PIDD participates in formation of multiprotein complexes such as the PIDDosome, linking genotoxic stress to caspase-2 activation and downstream cell fate decisions. Beyond apoptosis, PIDD has been associated with centrosome-related processes and DNA damage signaling that influence cell cycle control and genomic stability. Dysregulation of these pathways is relevant to studies of cancer biology, neurodevelopmental phenotypes, and other conditions where stress signaling, apoptosis, or chromosome maintenance are perturbed.
PIDD CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PIDD1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PIDD1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PIDD1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PIDD protein expression.
This CRISPR knockout system enables efficient generation of PIDD1-deficient cell models for investigation of PIDD signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PIDD1 exon(s) critical for PIDD function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PIDD1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PIDD CRISPR/Cas9 KO Plasmid (h) and PIDD CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PIDD1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PIDD HDR Plasmid (h) and PIDD HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PIDD1 homology arms to support homology-directed repair at defined PIDD1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.